share_log

賽生藥業:根據收購守則規則3.8刊發的公告

SCICLONE PHARMA: ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

Hong Kong Stock Exchange ·  Apr 22 09:56
Summary by Moomoo AI
賽生藥業控股有限公司於2024年4月22日發布公告,提及Silver Pegasus Investment Limited擬以協議安排方式私有化賽生藥業。該私有化建議首次於2024年3月28日的聯合公告中提出。此外,賽生藥業亦披露了其購股權激勵計劃的最新情況,包括2018年6月24日批准的購股權激勵計劃和2021年1月22日股東決議通過的首次公開發售後購股權計劃。根據這些計劃,公司已發行新股份及購股權。截至公告日期,賽生藥業的已發行股份總數為628,474,132股,並有68,337,132份購股權。公司董事會對公告內容的準確性承擔責任,並確認經過合理查詢後,公告內容無遺漏事實,不會導致誤導。
賽生藥業控股有限公司於2024年4月22日發布公告,提及Silver Pegasus Investment Limited擬以協議安排方式私有化賽生藥業。該私有化建議首次於2024年3月28日的聯合公告中提出。此外,賽生藥業亦披露了其購股權激勵計劃的最新情況,包括2018年6月24日批准的購股權激勵計劃和2021年1月22日股東決議通過的首次公開發售後購股權計劃。根據這些計劃,公司已發行新股份及購股權。截至公告日期,賽生藥業的已發行股份總數為628,474,132股,並有68,337,132份購股權。公司董事會對公告內容的準確性承擔責任,並確認經過合理查詢後,公告內容無遺漏事實,不會導致誤導。
Caisang Pharmaceutical Holdings Limited issued a notice on 22 April 2024 indicating that Silver Pegasus Investment Limited intends to privatize its pharmaceutical business by agreement. The privatisation proposal was first proposed in the Joint Announcement of 28 March 2024. In addition, Caisang Pharmaceuticals disclosed updates on its Share Rights Incentive Program, including the Share Option Incentive Plan approved on June 24, 2018 and the Initial Public Offering Possession Option Plan approved by the Shareholders' Resolution on January 22, 2021. Under these plans, the Company has issued new shares and share purchase options. As of the date of the announcement, the total number of shares issued in Caisang Pharmaceuticals is 628,474,132 shares and has 68,337,132 share options. The Board of Directors is responsible for the accuracy of the contents of the announcement and verifies, after reasonable enquiries, that the content of the announcement is not missing facts and does not lead to misrepresentation.
Caisang Pharmaceutical Holdings Limited issued a notice on 22 April 2024 indicating that Silver Pegasus Investment Limited intends to privatize its pharmaceutical business by agreement. The privatisation proposal was first proposed in the Joint Announcement of 28 March 2024. In addition, Caisang Pharmaceuticals disclosed updates on its Share Rights Incentive Program, including the Share Option Incentive Plan approved on June 24, 2018 and the Initial Public Offering Possession Option Plan approved by the Shareholders' Resolution on January 22, 2021. Under these plans, the Company has issued new shares and share purchase options. As of the date of the announcement, the total number of shares issued in Caisang Pharmaceuticals is 628,474,132 shares and has 68,337,132 share options. The Board of Directors is responsible for the accuracy of the contents of the announcement and verifies, after reasonable enquiries, that the content of the announcement is not missing facts and does not lead to misrepresentation.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more